Table 1. Baseline characteristics of patients with advanced bone and soft tissue sarcomas referred to an early phase clinical trial clinic

Characteristic	No. of patients (%)
Age at Diagnosis: Mean [range], y	52 (20-83)
Age at ECT referral: Median [range], y	54 (21-83)
>65	23 (31)
Male	42 (57)
Sarcoma Type	
Bone	16 (22)
Soft Tissue	58 (78)
Primary Sarcoma Site	
Extremity	18 (24)
Trunk/axial/breast	15 (20)
Intra-abdominal/pelvic	34 (46)
Head and Neck	6 (8)
Histological subtype	
Leiomyosarcoma	17 (23)
Liposarcoma	10 (14)
Angiosarcoma	8 (11)
Osteosarcoma	7 (10)
Undifferentiated pleomorphic sarcoma	6 (8)
Synovial Sarcoma	3 (4)
Chordoma	3 (4)
Sarcoma NOS	3 (4)
Alveolar soft part sarcoma	2 (3)
Chondrosarcoma*	2 (3)
Rhabdomyosarcoma†	2 (3)
Sarcoma NOS	2 (3)
Other‡	17 (23)
Treatment modalities	
Surgery	64 (87)
Radiation therapy	51 (69)
Systemic agents	73 (99)
Number of systemic regimens (including ECT)	
0	1 (1)
1	8 (11)
2	23 (31)
3	16 (22)
4	12 (16)
≥5	14 (19)
Molecular Characteristics	
TMB	
low	62 (84)
high	7 (9)
indeterminate	2 (3)
unknown	3 (4)
Microsatellite status	
stable	66 (89)
unknown	8 (11)
Actionable mutation	
Yes	40 (54)
No	31 (42)
Unknown	3 (4)
Recruited to ECT	36 (49;100])
Screen fail	1

Characteristic	No. of patients (%)
Phase	
1	12 (16; 33)
2	24 (32; 67)
Investigation product	
Immunotherapeutic[§]	20 [27; 56)
Combination immune/targeted[§]	10 (14; 28)
Chemotherapy[§]	6 (8; 17
Targeted therapy	2 (3; 6)
Matched trial	20 (27; 56)
High TMB to immunotherapeutic	5 (7;14)
ECT at our institution	3 (4; 8)
ECT at external institution	2 (3; 6)
Actionable mutation to targeted therapy/combination[‖]	15 (20; 42)
ECT at our institution	12 (16; 33)
ECT at external institution	3 (4; 8)

Abbrev. ECT, early phase clinical trial
**dedifferentiated (1), mesenchymal (1)*
[†]*spindle cell (1), alveolar (1)*
[‡]*Other histological subtypes (1 each): desmoplastic small round cell tumour (DSCRT), endometrial stromal sarcoma, extraosseous Ewing sarcoma, extraskeletal myxoid chondrosarcoma, gastrointestinal stroma tumour, inflammatory myofibroblastic tumour, malignant peripheral nerve sheath tumour, pleomorphic intimal sarcoma, pleomorphic sarcoma of bone, sclerosing epithelioid fibrosarcoma, solitary fibrous tumour; TMB, tumour mutational burden*
[§]*2 patients were recruited to 2 different ECTs*
[‖]*CDK4 amplification (6), CDKN2A/B loss (5), CCND2 (1), RAF fusion (2), BRCA1/ATM (1)*